MEMBER'S LOGINX
| Invalid Username / Password | ||||||||
| Invalid Captcha | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Company Info
- Quarterly Company Results - March 2020
"Pharmaceuticals" Company Results for March 2020 Quarter 
Here are the latest quarterly results of India's top pharmaceuticals companies. For more detailed updates, read our pharmaceuticals sector report and check the latest pharmaceuticals sector stock quotes.
| Click on title to sort | Mar 2019 | Mar 2020 | YoY %-Change | Get More Info | ||||
|---|---|---|---|---|---|---|---|---|
Name |
Net Sales (Rs m) |
PAT (Rs m) |
Net Sales (Rs m) |
PAT (Rs m) |
Net Sales (%) |
PAT (%) |
P/E* (x) |
|
| ABBOTT INDIA | 9,063 | 1,132 | 9,612 | 1,110 | 6.1% | -2.0% | 27.8 | More Info
|
| ADLINE CHEM LAB | 10 | 18 | 14 | -5 | 30.8% | -128.8% | N.A. | More Info
|
| ADVANCED ENZYME TECHNOLOGIES | 1,104 | 335 | 1,103 | 327 | -0.1% | -2.3% | 26.1 | More Info
|
| ADVIK LABORS | 0 | -3 | 0 | -4 | N.A. | N.A. | N.A. | More Info
|
| AJANTA PHARMA | 5,152 | 889 | 6,820 | 1,292 | 32.4% | 45.3% | 30.4 | More Info
|
| ALBERT DAVID | 677 | 74 | 600 | -33 | -11.4% | -144.5% | 3.9 | More Info
|
| ALCHEMIST LIMITED | 57 | 74 | 13 | -398 | -77.5% | -635.5% | N.A. | More Info
|
| ALPA LAB | 0 | 0 | 182 | -23 | N.A. | N.A. | 4.3 | More Info
|
| AMBALAL SARABHAI | 448 | 10 | 386 | 143 | -13.9% | 1,277.2% | 64.6 | More Info
|
| ANUH PHARMA | 830 | 53 | 721 | -9 | -13.2% | -117.3% | 12.2 | More Info
|
| ASHRAM ONLINE | 0 | 2 | 1 | 4 | 207.1% | 61.2% | N.A. | More Info
|
| ASPIRA PATHLAB & DIAGNOSTICS | 21 | -12 | 20 | -13 | -5.2% | N.A. | N.A. | More Info
|
| ASTER DM HEALTHCARE | 22,010 | 2,202 | 23,014 | 1,461 | 4.6% | -33.6% | 19.5 | More Info
|
| ASTRAZENECA PHARMA | 1,903 | 98 | 1,949 | 96 | 2.4% | -2.5% | 76.9 | More Info
|
| AURO LAB. | 115 | 16 | 94 | 5 | -18.2% | -70.7% | 9.4 | More Info
|
| AUROBINDO PHARMA | 52,922 | 5,857 | 61,584 | 8,825 | 16.4% | 50.7% | 20.0 | More Info
|
| AUROBINDO PHARMA | 52,922 | 5,857 | 61,584 | 8,825 | 16.4% | 50.7% | 20.0 | More Info
|
| AUROBINDO PHARMA | 52,922 | 5,857 | 61,584 | 8,825 | 16.4% | 50.7% | 20.0 | More Info
|
| AUROBINDO PHARMA | 52,922 | 5,857 | 61,584 | 8,825 | 16.4% | 50.7% | 20.0 | More Info
|
| BACIL PHARMA | 0 | -1 | 0 | -0 | N.A. | N.A. | N.A. | More Info
|
| BAFNA PHARMA | 95 | -151 | 131 | 6 | 38.3% | N.A. | 31.5 | More Info
|
| BAJAJ HEALTHCARE | 0 | 0 | 1,185 | 126 | N.A. | N.A. | 67.7 | More Info
|
| BDH INDUS. | 81 | 6 | 125 | 12 | 53.7% | 109.3% | 5.6 | More Info
|
| BERYL DRUGS | 24 | 1 | 31 | -5 | 29.1% | -601.9% | 3.7 | More Info
|
| BHARAT PARENTALS | 411 | 52 | 548 | 71 | 33.1% | 36.3% | 14.8 | More Info
|
| BIOFIL CHEMICALS | 25 | 0 | 37 | 1 | 50.2% | 635.0% | 395.2 | More Info
|
| BRAWN BIOTECH | 154 | 3 | 67 | -3 | -56.8% | -206.2% | N.A. | More Info
|
| BROOKS LAB | 152 | -69 | 188 | -160 | 24.2% | N.A. | 361.4 | More Info
|
| CHEMO PHARMA | 0 | 2 | 0 | 0 | N.A. | -92.2% | 3.8 | More Info
|
| CHOKSI LAB. | 91 | 7 | 62 | -24 | -31.7% | -424.3% | 2.0 | More Info
|
| COLINZ LABOR | 17 | 0 | 17 | -0 | -2.1% | -191.7% | 6.3 | More Info
|
| CONCORD DRUGS | 144 | 2 | 131 | 1 | -9.0% | -42.9% | 22.3 | More Info
|
| CORAL LAB. | 193 | -12 | 206 | 35 | 6.6% | N.A. | 11.9 | More Info
|
| DENIS CHEM LAB | 275 | 17 | 313 | 2 | 13.7% | -90.1% | 6.7 | More Info
|
| DESH RAKSHAK | 20 | 1 | 20 | 1 | -1.1% | -28.2% | 4.5 | More Info
|
| DR HABEEBULLAH LIFE SCIENCES | 6 | -5 | 2 | -4 | -61.0% | N.A. | N.A. | More Info
|
| DR. LAL PATHLABS | 3,011 | 474 | 3,017 | 326 | 0.2% | -31.2% | 60.0 | More Info
|
| DR. REDDYS LAB | 40,296 | 4,397 | 44,489 | 7,706 | 10.4% | 75.3% | 16.9 | More Info
|
| EVEREST ORGANICS | 521 | 9 | 463 | 40 | -11.1% | 319.7% | 1,102.8 | More Info
|
| FDC | 2,707 | 364 | 3,333 | 559 | 23.2% | 53.5% | 18.3 | More Info
|
| FERMENTA BIOTECH | 916 | 385 | 645 | 31 | -29.5% | -91.9% | N.A. | More Info
|
| FERVENT SYNERGIES | 37 | -0 | 7 | 0 | -79.6% | N.A. | 75.8 | More Info
|
| FORTIS MALAR | 352 | 5 | 222 | -25 | -37.0% | -572.4% | N.A. | More Info
|
| FREDUN PHARMA | 322 | 11 | 244 | -2 | -24.2% | -119.2% | 13.1 | More Info
|
| GENNEX LAB. | 204 | 4 | 115 | 3 | -43.8% | -32.2% | 11.7 | More Info
|
| GLENMARK PHARMA | 25,635 | 1,617 | 27,675 | 2,203 | 8.0% | 36.3% | N.A. | More Info
|
| GODAVARI DRU | 247 | 4 | 244 | 8 | -0.9% | 108.0% | 8.1 | More Info
|
| GSK PHARMA | 7,508 | 1,468 | 7,758 | 1,381 | 3.3% | -6.0% | 49.0 | More Info
|
| GUFIC BIOSCIENCE | 915 | 60 | 871 | 50 | -4.9% | -17.3% | 14.3 | More Info
|
| GUJ.INJ(KER) | 0 | -0 | 0 | 0 | N.A. | N.A. | 46.3 | More Info
|
| GUJ.TERC LAB | 80 | 4 | 93 | -6 | 16.5% | -258.2% | 10.9 | More Info
|
| GUJ.THEMIS. | 104 | 25 | 264 | 110 | 154.4% | 335.1% | 33.5 | More Info
|
| HEALTHCARE GLOBAL ENTER. | 2,579 | -56 | 2,704 | -489 | 4.8% | N.A. | 93.1 | More Info
|
| HESTER BIOSCIENCES | 522 | 135 | 436 | 48 | -16.5% | -64.7% | 90.6 | More Info
|
| HULTA PHARMA | 0 | -0 | 0 | -0 | N.A. | N.A. | N.A. | More Info
|
| IND SWIFT LA | 1,941 | -252 | 1,917 | 33 | -1.2% | N.A. | 10.3 | More Info
|
| IND. SWIFT | 737 | 140 | 835 | -47 | 13.4% | -133.7% | 0.8 | More Info
|
| INDOCO REMEDIES | 2,521 | 115 | 2,720 | 54 | 7.9% | -53.4% | 28.3 | More Info
|
| INDRAPRASTHA MEDICAL | 2,004 | 71 | 2,005 | 65 | 0.0% | -9.0% | 4.7 | More Info
|
| INTRA INFOTECH | 0 | -9 | 0 | -27 | N.A. | N.A. | N.A. | More Info
|
| IOL CHEMICALS & PHARM. | 4,223 | 1,017 | 4,415 | 903 | 4.5% | -11.2% | 25.1 | More Info
|
| IPCA LABS | 8,796 | 970 | 10,738 | 854 | 22.1% | -11.9% | 87.6 | More Info
|
| ISHITA DRUGS | 30 | 1 | 34 | 2 | 13.9% | 52.6% | 15.4 | More Info
|
| ISTREET NETWORK | 0 | -2 | 0 | -0 | N.A. | N.A. | N.A. | More Info
|
| J.B.CHEMICALS | 4,189 | 468 | 4,436 | 501 | 5.9% | 7.0% | 31.9 | More Info
|
| JAGSON PHAR | 384 | 30 | 571 | 54 | 48.7% | 82.5% | 8.5 | More Info
|
| JENBURKT PH. | 351 | 69 | 303 | 46 | -13.8% | -33.0% | 7.6 | More Info
|
| JUBILANT INDUSTRIES | 1,424 | -52 | 1,242 | -12 | -12.8% | N.A. | 22.1 | More Info
|
| JUBILANT PHARMOVA | 23,856 | -1,007 | 23,914 | 2,605 | 0.2% | N.A. | N.A. | More Info
|
| KABRA DRUGS | 0 | -0 | 0 | -0 | N.A. | N.A. | N.A. | More Info
|
| KERALA AYURV | 151 | 3 | 187 | -6 | 24.2% | -281.4% | N.A. | More Info
|
| KILITCH DRUGS | 192 | 5 | 116 | -12 | -39.4% | -351.2% | 12.2 | More Info
|
| KIMIA BIOSCIENCES | 189 | -0 | 213 | -8 | 12.4% | N.A. | N.A. | More Info
|
| KOPRAN. | 997 | 77 | 874 | 48 | -12.4% | -37.4% | 15.1 | More Info
|
| KOVAI MEDICAL | 1,593 | 154 | 1,778 | 335 | 11.6% | 117.6% | 7.5 | More Info
|
| KREBS BIOCHEMICALS | 117 | -52 | 148 | -62 | 26.0% | N.A. | N.A. | More Info
|
| LACTOSE INDIA | 92 | 2 | 99 | -1 | 7.7% | -148.6% | 5.8 | More Info
|
| LASA SUPERGENERICS | 420 | -18 | 486 | 26 | 15.6% | N.A. | N.A. | More Info
|
| LINK PHARMA | 47 | -5 | 58 | 3 | 22.5% | N.A. | N.A. | More Info
|
| LOOKS HEALTH SERVICES | 2 | -1 | 2 | -4 | -38.2% | N.A. | N.A. | More Info
|
| MAKERS LAB. | 80 | 8 | 0 | 0 | -100.0% | -100.0% | N.A. | More Info
|
| MANGALAM DRUGS | 481 | -60 | 881 | 51 | 83.2% | N.A. | N.A. | More Info
|
| MARKSANS PHARMA. | 2,474 | 99 | 3,353 | 427 | 35.5% | 333.8% | 8.4 | More Info
|
| MEDI CAPS | 155 | 22 | 78 | -9 | -49.6% | -141.8% | N.A. | More Info
|
| MEDICAMEN BI | 0 | 0 | 235 | 25 | N.A. | N.A. | 51.3 | More Info
|
| MERCURY LAB. | 121 | 2 | 118 | -4 | -2.5% | -260.2% | 20.3 | More Info
|
| MESCO PHARMA | 0 | -0 | 0 | -0 | N.A. | N.A. | N.A. | More Info
|
| METROPOLIS HEALTHCARE | 2,019 | 352 | 2,070 | 155 | 2.5% | -56.0% | 88.8 | More Info
|
| NARAYANA HRUDAYALAYA | 7,652 | 335 | 7,429 | 124 | -2.9% | -62.8% | 12.6 | More Info
|
| NATCO PHARMA | 4,557 | 1,204 | 4,548 | 932 | -0.2% | -22.6% | 13.2 | More Info
|
| NATURAL CAPS | 158 | 9 | 157 | 1 | -1.2% | -87.9% | 11.7 | More Info
|
| NECTAR LIFESCIENCE | 7,957 | 175 | 5,648 | 74 | -29.0% | -57.6% | 63.2 | More Info
|
| NGL FINE CHM | 435 | 68 | 354 | -2 | -18.4% | -102.8% | 19.8 | More Info
|
| NORRIS MEDICINES | 36 | 9 | 14 | -6 | -59.8% | -162.6% | N.A. | More Info
|
| NOVARTIS | 1,104 | 195 | 937 | 68 | -15.1% | -65.3% | 17.8 | More Info
|
| NUTRAPLUS PR | 358 | 5 | 138 | -320 | -61.6% | -6,248.8% | N.A. | More Info
|
| ORCHID PHARMA | 1,621 | -134 | 1,115 | -389 | -31.2% | N.A. | 7.8 | More Info
|
| ORTIN LABS | 469 | 17 | 722 | 17 | 53.9% | -1.4% | N.A. | More Info
|
| PANACEA BIOTECH | 1,196 | 1,835 | 1,254 | -686 | 4.8% | -137.4% | N.A. | More Info
|
| PANACEA BIOTECH | 1,196 | 1,835 | 1,254 | -686 | 4.8% | -137.4% | N.A. | More Info
|
| PANCHSHEEL ORG | 100 | 8 | 121 | 12 | 20.4% | 65.4% | 8.0 | More Info
|
| PARENT.DRUGS | 38 | -720 | 88 | -319 | 131.8% | N.A. | N.A. | More Info
|
| PARMAX PHARMA | 32 | 9 | 44 | -9 | 35.4% | -202.2% | N.A. | More Info
|
| PATIDAR BUILDCON | 4 | 0 | 4 | -0 | -2.9% | -186.8% | N.A. | More Info
|
| PFIZER | 5,357 | 1,095 | 5,020 | 1,030 | -6.3% | -5.9% | 47.3 | More Info
|
| PHAARMASIA | 126 | 12 | 55 | 5 | -56.6% | -55.3% | N.A. | More Info
|
| PHARMAIDS PH | 0 | -1 | 0 | 4 | N.A. | N.A. | N.A. | More Info
|
| RAYMED LABS | 0 | -0 | 0 | -0 | N.A. | N.A. | N.A. | More Info
|
| REKVINA LABS | 0 | -2 | 0 | -1 | N.A. | N.A. | N.A. | More Info
|
| ROOPA INDUSTRIES | 115 | 3 | 58 | 1 | -49.7% | -78.5% | 6.8 | More Info
|
| RUBRA MEDICA | 3 | 1 | 6 | -0 | 110.0% | -103.8% | 7.5 | More Info
|
| S.S.ORGANICS | 38 | -13 | 22 | -5 | -42.1% | N.A. | N.A. | More Info
|
| SAMRAT PHARMA | 364 | 13 | 303 | 4 | -16.9% | -69.7% | 1,837.0 | More Info
|
| SANDU PHARMA | 119 | 0 | 110 | 2 | -7.6% | 888.2% | 30.1 | More Info
|
| SANJIVANI PA | 54 | 3 | 38 | -2 | -28.7% | -176.3% | 2.1 | More Info
|
| SCANDENT IMAGING | 51 | 13 | 32 | 0 | -38.2% | -99.6% | 13.3 | More Info
|
| SEQUENT SCIENTIFIC | 2,819 | 213 | 3,006 | 182 | 6.6% | -14.5% | N.A. | More Info
|
| SHABA CHEM. | 0 | -0 | 0 | -0 | N.A. | N.A. | 12.1 | More Info
|
| SHAMROCK IND | 0 | -65 | 0 | -1 | N.A. | N.A. | N.A. | More Info
|
| SHILPA MEDICARE | 1,995 | 225 | 2,200 | 344 | 10.3% | 53.0% | 822.9 | More Info
|
| SHUKRA PHARMA | 26 | 2 | 40 | -4 | 55.4% | -267.8% | 10.3 | More Info
|
| SHYAMA INFOSYS | 1 | 0 | 1 | 0 | -56.4% | N.A. | 14.9 | More Info
|
| SMS LIFESCIENCES INDIA | 0 | 0 | 460 | 16 | N.A. | N.A. | 90.1 | More Info
|
| SMS PHARMA | 1,037 | 65 | 965 | 62 | -7.0% | -3.5% | 24.6 | More Info
|
| SONI MEDICARE | 42 | -3 | 32 | -7 | -24.3% | N.A. | N.A. | More Info
|
| SOURCE NATURAL FOODS | 46 | -0 | 38 | 5 | -17.9% | N.A. | 35.3 | More Info
|
| STRIDES PHARMA SCIENCE | 6,162 | 798 | 6,186 | -1,626 | 0.4% | -303.7% | N.A. | More Info
|
| SUN PHARMA | 71,639 | 7,231 | 81,849 | 4,944 | 14.3% | -31.6% | 16.1 | More Info
|
| SUNIL HEALTHCARE | 191 | -5 | 161 | -6 | -15.8% | N.A. | N.A. | More Info
|
| SUVEN LIFE SCIENCES | 24 | -394 | 87 | -256 | 263.9% | N.A. | N.A. | More Info
|
| SWAGRUHA INFRA | 2 | 0 | 0 | -0 | -85.7% | -187.8% | 103.2 | More Info
|
| SYNCOM FORMULATIONS | 612 | 22 | 430 | 35 | -29.7% | 59.1% | 13.5 | More Info
|
| SYNCOM HEALTHCARE | 117 | -90 | 2 | -97 | -98.7% | N.A. | N.A. | More Info
|
| TEJNAKSH HEALTHCARE | 51 | 13 | 35 | -1 | -30.7% | -104.0% | 82.8 | More Info
|
| THEMIS MEDICARE | 357 | -93 | 462 | 52 | 29.2% | N.A. | 114.6 | More Info
|
| TORRENT PHARMA | 18,560 | -1,520 | 19,460 | 3,140 | 4.8% | N.A. | 62.7 | More Info
|
| TRANS ASIA CORP | 0 | -13 | 0 | -0 | N.A. | N.A. | N.A. | More Info
|
| TRIMURTHI DRUGS | 105 | -1 | 27 | 0 | -74.5% | N.A. | N.A. | More Info
|
| TTK HEALTHCARE | 1,396 | 50 | 1,365 | 4 | -2.2% | -91.5% | 12.4 | More Info
|
| UNICHEM LAB | 3,749 | 318 | 3,202 | -178 | -14.6% | -155.9% | 132.7 | More Info
|
| UNJHA FORMUL | 32 | -1 | 27 | -3 | -17.4% | N.A. | 18.3 | More Info
|
| VASUNDHARA RASAYANS | 51 | -7 | 50 | 8 | -2.7% | N.A. | 6.5 | More Info
|
| VENUS REMEDIES | 904 | -115 | 831 | -54 | -8.2% | N.A. | 7.3 | More Info
|
| VISTA PHARMA | 122 | 7 | 8 | -42 | -93.3% | -741.8% | N.A. | More Info
|
| VIVANZA BIOSCIENCES | 13 | -2 | 60 | 5 | 345.9% | N.A. | 602.8 | More Info
|
| WANBURY | 1,016 | -99 | 671 | 624 | -34.0% | N.A. | 7.5 | More Info
|
| WOCKHARDT | 8,613 | -274 | 6,869 | 487 | -20.2% | N.A. | N.A. | More Info
|
| WOCKHARDT | 8,613 | -274 | 6,869 | 487 | -20.2% | N.A. | N.A. | More Info
|
| ZENITH HEALTH | 22 | -1 | 22 | 2 | 2.8% | N.A. | 322.9 | More Info
|
| ZENLABS ETHICA | 189 | 1 | 153 | -1 | -19.3% | -160.2% | N.A. | More Info
|
| ZIM LABORATORIES | 946 | 23 | 692 | 23 | -26.8% | -0.3% | 27.6 | More Info
|
| ZYDUS LIFESCIENCES | 37,328 | 4,792 | 37,521 | 4,135 | 0.5% | -13.7% | 16.6 | More Info
|
| ZYDUS LIFESCIENCES | 37,328 | 4,792 | 37,521 | 4,135 | 0.5% | -13.7% | 16.6 | More Info
|
| Sector Aggregate | 637,558 | 60,792 | 691,101 | 73,511 | 8.4% | 20.9% | ||
* Trailing 12 months earnings, excluding extraordinary / exceptional items. |
Dec 2019 Results | Jun 2020 Results | Latest Quarter Results | View All Results |
|||||||
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks
TRENDING TOPICS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407
Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com
LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.